Ajanta Pharma Poised To Deliver Double Digit Growth, Says Systematix

Ajanta Pharma Ltd., a leading Indian pharmaceutical company, has reported strong Q1 FY26 results, exceeding market expectations. The company’s revenue stood at Rs 13,027 million, up 13.8% YoY and 11.3% QoQ.

The strong growth was driven by a significant increase in revenue from North America, which rose 36% YoY, and branded formulation in India, which grew by 16% YoY.

Ajanta Pharma’s Ebitda stood at Rs 3.51 billion, up 6.4% YoY and 18.2% QoQ, while its Ebitda margin stood at 27%, down 188 bps YoY and up 158 bps QoQ. PAT stood at Rs 2.5 billion, up 3.9% YoY and 13.4% QoQ, and PAT margin stood at 19.6%, down 186 bps YoY and up 36 bps QoQ.

Key Highlights:

• Ajanta Pharma’s Q1 FY26 revenue surpassed market expectations.
• The company’s revenue from North America grew 36% YoY, driven by strong demand for its products.
• Ajanta Pharma’s branded formulation business in India grew by 16% YoY, driven by the launch of new products.
• The company plans to expand its sales force in Emerging Markets by 10% this year and add around 150 medical representatives in India to support newly launched therapies.
• Ajanta Pharma maintains its guidance for double-digit growth in FY26.

Analyst’s Take:

Systematix has reiterated its ‘Buy’ rating on Ajanta Pharma with a target price of Rs 3,293, based on 35x FY27E earnings per share. The analyst believes that the company’s strong growth momentum and expansion in emerging markets will sustain its double-digit growth.

Ajanta Pharma’s focus on branded formulation and its ability to launch new products in key markets are expected to drive growth in the near term.

What’s Ahead?

Ajanta Pharma is expected to report strong revenue growth in the coming quarters, driven by its expanding product portfolio and increasing demand for its products in key markets.

The company’s focus on emerging markets and its plans to expand its sales force in these regions will also support its growth momentum.

Conclusion:

Ajanta Pharma’s strong Q1 FY26 results demonstrate its ability to deliver strong growth in a competitive industry. The company’s focus on branded formulation, expansion in emerging markets, and strong demand for its products in key markets make it an attractive investment opportunity.

Ajanta Pharma is poised to deliver double-digit growth in FY26, driven by its strong growth momentum and expansion in emerging markets.

With its strong track record and growth potential, Ajanta Pharma is a stock that investors should consider adding to their portfolios.